Lantheus Holdings

LNTH30 Nov 2024
Healthcare
$91.13
-0.01 (-1.11%)
Lowest Today
$89.2
Highest Today
$91.21
Today’s Open
$91.13
Prev. Close
$90.27
52 Week High
$126.89
52 Week Low
$50.2
To Invest in Lantheus Holdings

Lantheus Holdings

Healthcare
LNTH30 Nov 2024
-0.01 (-1.11%)
1M
3M
6M
1Y
5Y
Low
$89.2
Day’s Range
High
$91.21
89.2
52 Week Low
$50.2
52-Week Range
52 Week High
$126.89
50.2
1 Day
-
1 Week
-1.87%
1 month return
-18.2%
3 month return
-16.06%
6 month return
+10.97%
1 Year return
+24.67%
3 Years return
+233.91%
5 Years return
+341.15%
10 Years return
-
Institutional Holdings
BlackRock Inc
12.36
Vanguard Group Inc
10.67
HHG PLC
4.79
Farallon Capital Management, L.L.C.
4.25
State Street Corp
3.58
FMR Inc
3.5
Vanguard Total Stock Mkt Idx Inv
3.18

Market Status

Fundamentals
Market Cap
6276.18 mln
PB Ratio
5.32
PE Ratio
15
Enterprise Value
6029.04 mln
Total Assets
1651.15 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Organisation
Lantheus Holdings
Employees
834
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Brian A. Markison
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities